The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders.
From doctors to patients, the goal of these publications is to help anyone better understand aspects of myeloma. The information provided in the International Myeloma Working Group’s publications seeks to help guide patients and their doctors to treating myeloma in the most effective way for every individual case.
IMWG Diagnostic Criteria
The revised diagnostic criteria include requirements for bone marrow plasma cells, serum free light chain ratio, MRI findings, myeloma bone disease, renal failure, monoclonal protein, and symptoms.
IMWG Response Criteria
The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease.
IMWG Smoldering Myeloma Risk Stratification
SMM is a precursor to multiple myeloma, with risk levels determined by protein levels, light-chain ratios, and cell infiltration. Early treatment may reduce progression risk.
IMWG Criteria for Plasma Cell Leukemia
Primary plasma cell leukemia requires ≥5% circulating plasma cells in MM patients. Early detection via blood tests is crucial. Disease is rare, aggressive, needs more research.
IMWG Relapsed Myeloma Guideline
The policy review presents recommendations from the International Myeloma Working Group for the treatment of relapsed and refractory multiple myeloma.
IMWG CART guideline
The management of relapsed or refractory multiple myeloma presents a significant clinical challenge, despite recent advancements in treatment modalities.
IMWG Bispecific Guideline
Bispecific antibody therapy can trigger cytokine release syndrome - an inflammatory reaction varying from mild to severe, typically occurring within 24h of treatment.
Bone Disease
In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease.
Infection Prevention
A consensus statement from the International Myeloma Working Group (IMWG) on infection prevention in patients with multiple myeloma.
Renal Failure
An overview of the management of renal impairment in multiple myeloma patients.
Vertebroplasty/ Kyphoplasty
Balloon kyphoplasty and vertebroplasty can treat vertebral fractures in multiple myeloma patients, reducing pain and disability when done within 4-8 weeks of injury.
Imaging
The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment.
Mass Spectrometry
Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce.
Whole Body Low Dose CT
Whole-body low-dose computed tomography (WBLDCT) is recommended as a first-line imaging modality for bone disease assessment in multiple myeloma patients.
Myeloma Drug Access
The study emphasizes the need for equal access to MM treatments in public settings and highlights barriers such as drug availability and high costs.
Predictors of Long term survival
This study examines the clinical predictors of long-term survival in multiple myeloma patients eligible for high-dose chemotherapy and autologous stem cell transplantation (HDM-ASCT).
Racial Disparities
This document discusses the disparities faced by African American patients with multiple myeloma in terms of incidence, timely diagnosis, access to treatment, clinical trial participation, and healthcare utilization.